文献速递胸部肿瘤

DNA测序识别的基因间断裂点融合干扰NSCLC可靶向激酶融合检测

Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC.
PubMed 文献 · J Thorac Oncol · 2020-03-07

该研究基于DNA的NGS在NSCLC中检出的基因间断裂点融合,用RNA-based NGS、IHC和FISH进行验证。26例中RNA-based NGS仅11例检出表达融合转录本,且基因组断裂点位置不能逻辑预测融合转录本断裂点;5例未检出表达转录本,3例IHC阳性但RNA-based NGS阴性。结论提示基因间断裂点融合需RNA/蛋白验证以指导治疗。

要点

  • DNA-based NGS检出的基因间断裂点融合需RNA或蛋白验证。
  • 基因组断裂点位置不能逻辑预测融合转录本断裂点。
  • RNA-based NGS阴性的基因间断裂点ALK融合仍可能IHC阳性。

核心结论

  • DNA测序检出的基因间断裂点融合可能产生也可能不产生功能性融合转录本,从而干扰激酶融合检测。
  • 对基因间断裂点融合病例应追加RNA或蛋白验证检测以指导最佳治疗。

研究设计与样本

  • 从大型NSCLC队列中经DNA-based NGS识别26例携带单一基因间断裂点融合的病例。
  • 对上述病例采用RNA-based NGS、免疫组化和荧光原位杂交进行分析。

主要发现

  • 26例中RNA-based NGS检出11例表达融合转录本,其基因组断裂点位置不能逻辑预测融合转录本断裂点,可能因复杂重排(n=5)、可变剪接(n=2)和相互重排(n=4)。
  • 5例未检出表达融合转录本。
  • 剩余10例中3例IHC检出ALK阳性而RNA-based NGS未检出。
  • 3例接受克唑替尼治疗的基因间断裂点ALK融合患者(有或无RNA-based NGS或IHC确认)出现部分缓解。
  • 1例基因间断裂点ROS1患者因FISH阳性接受克唑替尼,但1个月内进展,可能因RNA-based NGS未检出功能性融合转录本。

临床怎么用

  • 对DNA-based NGS检出的基因间断裂点融合,应追加RNA-based NGS或IHC等验证检测。
  • 基因间断裂点ALK融合患者接受克唑替尼治疗可能获得部分缓解。
  • RNA-based NGS未检出功能性融合转录本的基因间断裂点ROS1患者接受克唑替尼可能短期内进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Next-generation sequencing (NGS) based on genomic DNA has been widely applied for gene rearrangement detection in patients with NSCLC. However, intergenic-breakpoint fusions, in which one or both genomic breakpoints localize to intergenic regions, confound kinase fusion detection. We evaluated the function of intergenic-breakpoint fusions with multiplex molecular testing approaches. METHODS: NSCLCs with intergenic-breakpoint fusion identified by DNA-based NGS were analyzed by RNA-based NGS, immunohistochemistry (IHC), and fluorescence in situ hybridization. RESULTS: A total of 26 cases with single intergenic-breakpoint fusion were identified from a large cohort of NSCLCs using DNA-based NGS. Of the 26 cases, RNA-based NGS detected expressed fusion transcripts in 11 cases, but the genomic breakpoint position did not logically predict breakpoint of the fusion transcript in these cases, possibly owing to complex rearrangements (n = 5), alternative splicing (n = 2), and reciprocal rearrangement (n = 4). Nonetheless, no expressed fusion transcript was detected in five cases. Moreover, positive anaplastic lymphoma receptor tyrosine (ALK) finding was observed in three of the remaining 10 cases with IHC but not with RNA-based NGS. Three patients with intergenic-breakpoint ALK fusion with or without RNA-based NGS or IHC confirmation who received crizotinib treatment were found to have partial responses. However, one patient with intergenic-breakpoint ROS1, given the positive fluorescence in situ hybridization result, received crizotinib but developed progressive disease within 1 month, possibly owing to no functional fusion transcript detected by RNA-based NGS. CONCLUSIONS: Intergenic-breakpoint fusions detected by DNA sequencing confound kinase fusion detection in NSCLC, as functional fusion transcripts may be generated or not. Additional validation testing using RNA/protein assay should be performed in intergenic-breakpoint fusion cases to guide optimal treatment.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Li W, Liu Y, Li W, et al. Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC. J Thorac Oncol. 2020. PMID: 32151779. doi:10.1016/j.jtho.2020.02.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。